Library · Heart, blood & kidney · Multiple myeloma, stem cell mobilization
Motixafortide
BL-8040
A 14-residue cyclic peptide CXCR4 blocker approved by the FDA in 2023 to mobilize blood stem cells for collection before autologous transplant in multiple myeloma. Combined with G-CSF, it produces fast, sustained release of stem cells into the blood.
Research score 84/100. Reference only, not a dose.
- Stem Cell Mobilization
- US status
- Prescription Only
- Approval
- FDA Approved (2023)
- Evidence
- GENESIS Phase 3 trial demonstrated superior stem cell mobilization vs placebo in combination with G-CSF
- Research score
- 84 / 100
- Indication
- Hematopoietic stem cell mobilization for autologous transplantation
- Origin
- United States
- Source category
- Blood & Hematology
- Status group
- Approved / prescription
Mechanism
Binds CXCR4 with high affinity, blocking SDF-1α/CXCL12 and freeing bone-marrow-anchored stem cells into circulation.
Safety file
Generally well tolerated when used together with G-CSF.
- Injection site reactions
- Bone pain (typical for mobilization regimens)